Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Medtech Lobbyists Say They're Not Worried About Political Backlash From 'Implant Files'

Executive Summary

The International Consortium of Investigative Journalists started publishing the findings of its "Implant Files" investigation last month, but the two main industry groups in the US have not picked up any significant political backlash resulting from the reporting so far.

You may also be interested in...



Ad Hominis: FDA Authorizes Memic Innovative’s Surgical Robot

The device can conduct laparoscopic hysterectomies, giving surgeons more mobility while leaving less scarring.

After A Year Of Pelvic Mesh Criticism, US FDA Calls Meeting To Discuss The Beleaguered Products

Following a number of reports and a major documentary criticizing the use of surgical mesh in transvaginal surgeries, regulators are calling on an expert panel and other stakeholders to provide recommendations on their safety and effectiveness. 

Into 2019: Intelligent Innovation's Role In The Shape Of Medtech Things To Come

Brexit, the "Implant Files" and the new EU regulations – however large they loom at present, they will in time be seen as mere tactical challenges for a global medtech industry working hard to ensure that it is ready for the massive health-care delivery and service-oriented changes to come. Preparing for the future and maximizing current market penetration – in the UK, the EU and beyond – were key themes at UK HealthTech 2018, held in Cardiff, Wales.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel